Curative Biotechnology, Inc. (CUBT)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Operating profit | $m | -2 | -1 | ||||||
| Net profit | $m | -5 | -5 | -5 | -4 | -4 | -2 | -2 | - |
| EPS reported | $ | -0.00 | -0.41 | ||||||
| Operating cashflow per share | $ | -0.00 | -0.12 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.00 | -0.12 | ||||||
| Free cash flow | $m | -1 | -1 | ||||||
| Net debt | $m | 1 | 1 | ||||||
| Book value equity | $m | -6 | -6 | ||||||
| Book value per share | $ | -0.01 | -0.77 | ||||||
| Number of shares | m | 1,017.59 | 8.26 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -135.42 | -129.00 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -948.65 | -801.66 | ||||||
| EV/EBITDA LTM | x | -583.76 | -721.76 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -0.27% | -32.84% | ||||||
| FCF Yield | % | -0.11% | -0.12% | ||||||
| Quality | |||||||||
| ROE | % | +37.18% | +33.00% | ||||||
| ROIC | % | +31.76% | +24.46% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.64 | -0.76 | ||||||
| Net Debt/EBITDA | x | -0.93 | -1.06 | ||||||
| EBIT/Net interest | x | -1.50 | -1.28 | ||||||
| Net debt/market cap | % | +0.16% | +26.51% | ||||||
| Net debt/Equity | x | -0.22 | -0.19 | ||||||
| Gross debt/equity | x | -0.22 | -0.21 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Curative Biotechnology, Inc. is an emerging biomedical firm primarily focused on developing pharmaceutical products. Its research and development efforts are concentrated on a diverse pipeline targeting critical therapeutic areas, including infectious diseases, cancer, and vision-impairing degenerative eye conditions. Among its key pipeline assets is IMT504, an innovative immunotherapy designed for rabies treatment and as a vaccine enhancer. Another prominent candidate is CUBT906, a fully humanized CD56 monoclonal antibody that delivers a pyrrolobenzodiazepine dimer directly to tumor cells, aiming to eradicate them by halting their growth and spread. Additionally, the company is advancing a reformulated Metformin for the management of degenerative eye disorders. Curative Biotechnology has entered into a licensing and co-development partnership with Mid-Atlantic BioTherapeutics, Inc. to further advance IMT504, specifically for addressing advanced rabies and as a component of a COVID-19 vaccine. Previously known as Connectyx Technologies Holdings Group, Inc., the company adopted its current name, Curative Biotechnology, Inc., in November 2020. Established in 1995, the company maintains its headquarters in Boca Raton, Florida.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Curative Biotechnology, Inc. is an emerging biomedical firm primarily focused on developing pharmaceutical products. Its research and development efforts are concentrated on a diverse pipeline targeting critical therapeutic areas, including infectious diseases, cancer, and vision-impairing degenerative eye conditions. Among its key pipeline assets is IMT504, an innovative immunotherapy designed for rabies treatment and as a vaccine enhancer. Another prominent candidate is CUBT906, a fully humanized CD56 monoclonal antibody that delivers a pyrrolobenzodiazepine dimer directly to tumor cells, aiming to eradicate them by halting their growth and spread. Additionally, the company is advancing a reformulated Metformin for the management of degenerative eye disorders. Curative Biotechnology has entered into a licensing and co-development partnership with Mid-Atlantic BioTherapeutics, Inc. to further advance IMT504, specifically for addressing advanced rabies and as a component of a COVID-19 vaccine. Previously known as Connectyx Technologies Holdings Group, Inc., the company adopted its current name, Curative Biotechnology, Inc., in November 2020. Established in 1995, the company maintains its headquarters in Boca Raton, Florida.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free